Ranbaxy Laboratories is reportedly looking to acquire US Food & Drug Administration (US FDA)-approved manufacturing facility in India to secure its future launches and shift some of its blockbuster drug filings in an attempt to reduce risks arising out of issues with its Mohali plant.
Last month, the US drug authorities had issued an import alert on Ranbaxy’s refurbished Mohali plant, halting sales from the last remaining US-compliant plant in India, for violation of good manufacturing practices.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
